Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Furst

Showing results (61-70 of 477) with videos related to

Pageof 48
Sort By:
Rheumatic Diseases Clinics of North America|July 5, 2003
Update on disease-modifying antirheumatic drugs in the treatment of systemic sclerosisAntony T H Lin, Philip J Clements, Daniel E Furst
Arthritis and Rheumatism|July 28, 2006
Gout and the risk of acute myocardial infarctionEswar Krishnan, Joshua F Baker, Daniel E Furst, et al.
The Journal of Rheumatology|December 19, 2007
Does incorporation of aids and devices make a difference in the score of the health assessment questionnaire-disability index? Analysis from a scleroderma clinical trialDinesh Khanna, Philip J Clements, Arnold E Postlethwaite, et al.
Seminars in Arthritis and Rheumatism|November 2, 2013
Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis SurveyMarie Hudson, Murray Baron, Solène Tatibouet, et al.
The Journal of Rheumatology|August 13, 2009
Thymoglobulin and cyclophosphamide as treatment for diffuse cutaneous systemic sclerosisLeona A Holmberg, Daniel E Furst, Peter A McSweeney, et al.
Statistical Methods in Medical Research|March 7, 2007
Assessing disease progression using a composite endpointWeng Kee Wong, Daniel E Furst, Philip J Clements, et al.
Arthritis Research & Therapy|September 15, 2007
Clinical trials in systemic sclerosis: lessons learned and outcomesMarco Matucci-Cerinic, Virginia D Steen, Daniel E Furst, et al.
International Journal of Rheumatology|December 12, 2017
Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDsWilliam F C Rigby, Kathy Lampl, Jason M Low, et al.
The Journal of Rheumatology|December 1, 2004
High dose immunotherapy with stem cell rescue in severe systemic sclerosis: an idea that is moving forwardDaniel E Furst, Richard Nash, Keith M Sullivan, et al.
Arthritis Care & Research|March 1, 2021
Discrepancy Between Multibiomarker Disease Activity and Clinical Disease Activity Scores in Patients With Persistently Active Rheumatoid ArthritisRoy Fleischmann, Jingyu Liu, Julie Zhu, et al.
Pageof 48

Showing results (61-70 of 477) with videos related to

Sort By:
Pageof 48
Rheumatic Diseases Clinics of North America|July 5, 2003
Update on disease-modifying antirheumatic drugs in the treatment of systemic sclerosisAntony T H Lin, Philip J Clements, Daniel E Furst
Arthritis and Rheumatism|July 28, 2006
Gout and the risk of acute myocardial infarctionEswar Krishnan, Joshua F Baker, Daniel E Furst, et al.
The Journal of Rheumatology|December 19, 2007
Does incorporation of aids and devices make a difference in the score of the health assessment questionnaire-disability index? Analysis from a scleroderma clinical trialDinesh Khanna, Philip J Clements, Arnold E Postlethwaite, et al.
Seminars in Arthritis and Rheumatism|November 2, 2013
Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis SurveyMarie Hudson, Murray Baron, Solène Tatibouet, et al.
The Journal of Rheumatology|August 13, 2009
Thymoglobulin and cyclophosphamide as treatment for diffuse cutaneous systemic sclerosisLeona A Holmberg, Daniel E Furst, Peter A McSweeney, et al.
Statistical Methods in Medical Research|March 7, 2007
Assessing disease progression using a composite endpointWeng Kee Wong, Daniel E Furst, Philip J Clements, et al.
Arthritis Research & Therapy|September 15, 2007
Clinical trials in systemic sclerosis: lessons learned and outcomesMarco Matucci-Cerinic, Virginia D Steen, Daniel E Furst, et al.
International Journal of Rheumatology|December 12, 2017
Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDsWilliam F C Rigby, Kathy Lampl, Jason M Low, et al.
The Journal of Rheumatology|December 1, 2004
High dose immunotherapy with stem cell rescue in severe systemic sclerosis: an idea that is moving forwardDaniel E Furst, Richard Nash, Keith M Sullivan, et al.
Arthritis Care & Research|March 1, 2021
Discrepancy Between Multibiomarker Disease Activity and Clinical Disease Activity Scores in Patients With Persistently Active Rheumatoid ArthritisRoy Fleischmann, Jingyu Liu, Julie Zhu, et al.
Pageof 48